KW-2449 | Multi-Kinase Inhibitor | AmBeed-信号通路专用抑制剂

KW-2449 {[allProObj[0].p_purity_real_show]}

货号：A306611

KW-2449 是一种多靶点激酶抑制剂，对FLT3、ABL、ABLT315I和Aurora激酶的IC50值分别为6.6 nM、14 nM、4 nM和48 nM。

KW-2449 化学结构
CAS号：1000669-72-6

KW-2449 3D分子结构
CAS号：1000669-72-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

转化生长因子-β 亚型比较

Aurora Kinase 亚型比较

FLT3 亚型比较

FGFR 亚型比较

Bcr-Abl 亚型比较

产品名称	ALK1 ↓ ↑	ALK2 ↓ ↑	ALK3 ↓ ↑	ALK4 ↓ ↑	ALK6 ↓ ↑	Smad3 ↓ ↑	TGF-β ↓ ↑	TGFβRI/ALK5 ↓ ↑	TGFβRII ↓ ↑	纯度
LDN193189	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%+
LDN-212854	++++ ALK1, IC50: 2.4 nM	++++ ALK2, IC50: 1.3 nM	+ ALK3, IC50: 85.8 nM	+ ALK4, IC50: 2133 nM				+ ALK5, IC50: 9276 nM		99%+
ML347	++ ALK1, IC50: 46 nM	++ ALK2, IC50: 32 nM								98%
K02288	++++ ALK1, IC50: 1.8 nM	++++ ALK2, IC50: 1.1 nM	++ ALK3, IC50: 34.4 nM		+++ ALK6, IC50: 6.4 nM					99%+
LDN-193189 2HCl	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%
LDN-214117		++ ALK2, IC50: 24 nM								98%
DMH-1		+ ALK2, IC50: 107.9 nM								99%+
SB-505124				+ ALK4, IC50: 129 nM				++ ALK5, IC50: 47 nM		99%+
Vactosertib				+++ ALK4, IC50: 13 nM				+++ ALK5, IC50: 11 nM		99%+
Alantolactone						✔				98%
(E/Z)-SIS3 free base						✔				97%
Pirfenidone							✔			98%
Hesperetin							✔			97%
RepSox								++++ TGFβR1(ALK5), IC50: 4 nM		98%
GW788388								+++ ALK5, IC50: 18 nM		98%
LY364947								++ TGFβRI, IC50: 59 nM	+ TGFβRII, IC50: 0.4 μM	98%
SD-208								++ TGF-βRI (ALK5), IC50: 48 nM		99%
SB-525334								+++ TGFβR1(ALK5), IC50: 14.3 nM		99%+
LY2109761								++ TβRI, Ki: 38 nM	+ TβRII, Ki: 300 nM	99%+
Galunisertib								++ TβRI, IC50: 56 nM		98%
SB 431542								+ ALK5, IC50: 94 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Aurora A ↓ ↑	Aurora B ↓ ↑	Aurora C ↓ ↑	其他靶点	纯度
BI-847325	++ Aurora A (Human), IC50: 25 nM	++++ Aurora B (Xenopus laevis), IC50: 3 nM	++ Aurora C (Human), IC50: 15 nM		99%+
CCT 137690	++ Aurora A, IC50: 15 nM	++ Aurora B, IC50: 25 nM	++ Aurora C, IC50: 19 nM		99%+
MK-5108	++++ Aurora A, IC50: 0.064 nM				99%+
KW-2449	+ Aurora A, IC50: 48 nM			FLT3	99%+
Tozasertib	++++ Aurora A, Ki app: 0.6 nM	++ Aurora B, Ki app: 18 nM	+++ Aurora C, Ki app: 4.6 nM	Bcr-Abl,FLT3	99%+
AT9283	++++ Aurora A, IC50: ~3.0 nM	++++ Aurora B, IC50: ~3.0 nM			99%+
MLN8054	+++ Aurora A, IC50: 4 nM	+ Aurora B, IC50: 172 nM			99%+
ZM-447439	+ Aurora A, IC50: 110 nM	+ Aurora B, IC50: 130 nM		Src	99%+
TCS7010	++++ Aurora A, IC50: 3.4 nM				99%+
TAK-901	++ Aurora A-TPX2, IC50: 21 nM	++ Aurora B-INCENP, IC50: 15 nM			99%+
Danusertib	+++ Aurora A, IC50: 13 nM	+ Aurora B, IC50: 79 nM	+ Aurora C, IC50: 61 nM	RET	99%+
MK-8745	++++ Aurora A, IC50: 0.6 nM				99+%
PHA-680632	++ Aurora A, IC50: 27 nM	+ Aurora B, IC50: 135 nM	+ Aurora C, IC50: 120 nM	FLT3	99%+
AMG 900	+++ Aurora A, IC50: 5 nM	+++ Aurora B, IC50: 4 nM	++++ Aurora C, IC50: 1 nM		99%+
Alisertib	++++ Aurora A, IC50: 1.2 nM				99%+
ENMD-2076	+++ Aurora A, IC50: 14 nM	+ Aurora B, IC50: 350 nM		RET,FLT3	98%
JNJ-7706621	+++ Aurora A, IC50: 11 nM	++ Aurora B, IC50: 15 nM			99%+
CYC-116	+++ Aurora A, Ki: 8 nM	+++ Aurora B, Ki: 9 nM		FLT3	99%+
Reversine	+++ Aurora A, IC50: 12 nM	+++ Aurora B, IC50: 13 nM	++ Aurora C, IC50: 20 nM		98%
CCT129202	++ Aurora A, IC50: 42 nM	+ Aurora B, IC50: 198 nM	+ Aurora C, IC50: 227 nM		98%
SNS-314 mesylate	+++ Aurora A, IC50: 9 nM	++ Aurora B, IC50: 31 nM	++++ Aurora C, IC50: 3 nM		99%+
Barasertib-HQPA		++++ Aurora B, IC50: 0.37 nM			99%+
Hesperadin		+ Aurora B (human), IC50: 250 nM			98%
GSK-1070916		++++ Aurora B-INCENP, IC50: 3.5 nM	+++ Aurora C-INCENP, IC50: 6.5 nM	SIK,Tie-2	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FLT3 ↓ ↑	其他靶点	纯度
R406	✔	Syk	98%
Go6976	✔		99%+
Quizartinib	+++ FLT3 (ITD), IC50: 1.1 nM FLT3 (WT), IC50: 4.2 nM		98%
Gilteritinib	++++ FLT3, IC50: 0.29 nM		99%+
Amuvatinib	+ FLT3 (D835Y), IC50: 81 nM		99%+
Pacritinib	++ FLT3 (D835Y), IC50: 6 nM FLT3, IC50: 22 nM		97%
Dovitinib	++++ FLT3, IC50: 1 nM	c-Kit	99%+
Denfivontinib	++++ FLT3 (D835Y), IC50: 0.4 nM FLT3, IC50: 0.4 nM	RET	99%+
TAK-659 HCl	++ FLT3, IC50: 4.6 nM	Syk	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FGFR ↓ ↑	FGFR1 ↓ ↑	FGFR2 ↓ ↑	FGFR3 ↓ ↑	FGFR4 ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ FGFR (Swiss 3T3), IC50: 12.3 μM					PDGFR	99%+
Pazopanib	+ FGFR, IC50: 140 nM						99%
Erdafitinib	✔					RET	99%+
Gambogenic acid	✔						98+%
Sulfatinib		+++ FGFR1, IC50: 15 nM					99+%
Nintedanib esylate		+ FGFR1, IC50: 69 nM	++ FGFR2, IC50: 37 nM	+ FGFR3, IC50: 108 nM			98%
Zoligratinib		+++ FGFR1, IC50: 9.3 nM	+++ FGFR2, IC50: 7.6 nM	++ FGFR3, IC50: 22 nM	+ FGFR4, IC50: 290 nM		99%+
MK-2461		+ FGFR1, IC50: 65 nM	++ FGFR2, IC50: 39 nM	++ FGFR3, IC50: 50 nM			98%+
SU 5402		++ FGFR1, IC50: 30 nM					98%
Brivanib		+ FGFR1, IC50: 148 nM					99%+
Lucitanib		++ FGFR1, IC50: 17.5 nM	+ FGFR2, IC50: 82.5 nM				99%+
Ponatinib		++++ FGFR1, IC50: 2.2 nM					98%
PD-166866		+ FGFR1, IC50: 52.4 nM					99%
Narazaciclib		++ FGFR1, IC50: 26 nM				RET	99%+
Lactate		+++ FGFR1, IC50: 8 nM		+++ FGFR3, IC50: 9 nM		c-Kit,FLT3	85%
Lenvatinib mesylate		++ FGFR1, IC50: 46 nM				c-RET	99%
LY2874455		++++ FGFR1, IC50: 2.8 nM	++++ FGFR2, IC50: 2.6 nM	+++ FGFR3, IC50: 6.4 nM	+++ FGFR4, IC50: 6 nM		99%+
FIIN-2		+++ FGFR1, IC50: 3.09 nM	+++ FGFR2, IC50: 4.3 nM	++ FGFR3, IC50: 27 nM	++ FGFR4, IC50: 45.3 nM		99%
FIIN-3		+++ FGFR1, IC50: 13.1 nM	++ FGFR2, IC50: 21 nM	++ FGFR3, IC50: 31.4 nM	++ FGFR4, IC50: 35.3 nM		98%
Infigratinib		++++ FGFR1, IC50: 0.9 nM	++++ FGFR2, IC50: 1.4 nM	++++ FGFR3, IC50: 1.0 nM FGFR3 (K650E), IC50: 4.9 nM	+ FGFR4, IC50: 60 nM		99%+
Danusertib		++ FGFR1, IC50: 47 nM				RET	99%+
R1530		++ FGFR1, IC50: 28 nM					98%
ENMD-2076		+ FGFR1, IC50: 92.7 nM	+ FGFR2, IC50: 70.8 nM			RET,FLT3	98%
Dovitinib		+++ FGFR1, IC50: 8 nM		+++ FGFR3, IC50: 9 nM		c-Kit,FLT3	99%+
Sorafenib		+ FGFR1, IC50: 580 nM					99%
SSR128129E		+ FGFR1, IC50: 1.9 μM					99%+
AZD-4547		++++ FGFR1, IC50: 0.2 nM	++++ FGFR2, IC50: 2.5 nM	++++ FGFR3, IC50: 1.8 nM			98%
Lenvatinib		++ FGFR1, IC50: 46 nM				RET	98%
PD173074		++ FGFR1, IC50: ~25 nM					99%+
S49076		++ FGFR1, IC50: 18 nM	+++ FGFR2, IC50: 17 nM	+++ FGFR3, IC50: 15 nM			98%
Futibatinib		++++ FGFR1, IC50: 1.8 nM	++++ FGFR2, IC50: 1.4 nM	++++ FGFR3, IC50: 1.6 nM	+++ FGFR4, IC50: 3.7 nM		99%+
Ferulic Acid		+ FGFR1, IC50: 3.78 μM	+ FGFR2, IC50: 12.5 μM				98%
Nintedanib		+ FGFR1, IC50: 69 nM	++ FGFR2, IC50: 37 nM	+ FGFR3, IC50: 108 nM	+ FGFR4, IC50: 610 nM		99+%
ASP5878		++++ FGFR1, IC50: 0.47 nM	++++ FGFR2, IC50: 0.6 nM	++++ FGFR3, IC50: 0.74 nM	+++ FGFR4, IC50: 3.5 nM		99%
PRN1371		++++ FGFR1, IC50: 0.6 nM	++++ FGFR2, IC50: 1.3 nM	+++ FGFR3, IC50: 4.1 nM	++ FGFR4, IC50: 19.3 nM		99%
Derazantinib		+++ FGFR1, IC50: 4.5 nM	++++ FGFR2, IC50: 1.8 nM	+++ FGFR3, IC50: 4.5 nM	++ FGFR4, IC50: 34 nM	RET	99%+
ODM-203		+++ FGFR1, IC50: 11 nM	+++ FGFR2, IC50: 16 nM	+++ FGFR3, IC50: 6 nM	++ FGFR4, IC50: 35 nM		99%+
Pemigatinib		++++ FGFR1, IC50: 0.4 nM	++++ FGFR2, IC50: 0.5 nM	++++ FGFR3, IC50: 1.2 nM	++ FGFR4, IC50: 30 nM		99%+
SKLB 610			✔			PDGFR	99%+
Alofanib			✔				99%+
Lirafugratinib			✔				99%
Masitinib mesylate				✔		FAK	99%+
BLU9931				+ FGFR3, IC50: 150 nM	+++ FGFR4, IC50: 3 nM		99%+
BO-264				✔			99%+
Fisogatinib					+++ FGFR4, IC50: 5 nM		99%+
H3B-6527					++++ FGFR4, IC50: <1.2 nM		99%+
Roblitinib					++++ FGFR4, IC50: 1.9 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Abl ↓ ↑	Bcr-Abl ↓ ↑	其他靶点	纯度
NVP-BHG 712	+ c-Abl, IC50: 1.667 μM			99%+
KW-2449	+++ Abl, IC50: 14 nM Abl (T315I), IC50: 4 nM		FLT3	99%+
Ponatinib	++++ Abl, IC50: 0.37 nM			98%
AT9283				99%+
Imatinib Mesylate	+ v-Abl, IC50: 600 nM		c-Kit,PDGFR	99%
Danusertib	++ Abl, IC50: 25 nM		RET	99%+
Rebastinib	++++ p-Abl1 (native), IC50: 0.75 nM u-Abl1 (T315I), IC50: 5 nM		Tie-2,FLT3	99%+
PP121	++ Abl, IC50: 18 nM		PDGFR,VEGFR	99%+
GNF-7	+++ E255V, IC50: 122 nM M351T, IC50: 133 nM			99%+
Olverembatinib dimesylate	++++ Abl (G250E), IC50: 0.35 nM Abl, IC50: 0.34 nM			98%
Dasatinib monohydrate	++++ Abl , IC50: 0.6 nM		Src	98%
Dasatinib	++++ Abl, IC50: 0.6 nM		Src	98%
Bafetinib	+++ Abl, IC50: 5.8 nM			98+%
GNF-2		+ Bcr-Abl (SUP-B15 cell line), IC50: 268 nM Bcr-Abl (K562 cell line), IC50: 273 nM		98%+
Degrasyn		+ Bcr-Abl, IC50: 1.8 μM	DUB/Deubiquitinase	99+%
GNF-5		++ Bcr-Abl, IC50: 220 nM		99%
Radotinib		++ BCR-ABL1, IC50: 34 nM		98+%
PD173955			Src	99%+
Nilotinib		++ Bcr-Abl, IC50: <30 nM		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

KW-2449 生物活性

靶点

Aurora A

Aurora A, IC50:48 nM
Abl

Abl, IC50:14 nM

Abl (T315I), IC50:4 nM

描述

KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A, and showing little effect on PDGFRβ, IGF-1R, EGFR.

KW-2449 细胞实验

Cell Line BV173/E255K human fibrosarcoma HT1080 cells Adult/T315I liver cancer HepG2 cells LAMA84 human lung cancer H1299 cells human colon cancer HT29 cells K562 neurons cerebral organoids RAW 264.7 cells mouse embryonic fibroblast cells (MEFs) human renal proximal tubule HK2 cells K562 LAMA84 BV173/E255K Adult/T315I	Concentration	Treated Time	Description	References
BV173/E255K	0.4 µM	48 h	KW2449 synergistically increased apoptosis with HDACIs	Clin Cancer Res. 2011 May 15;17(10):3219-32.
human fibrosarcoma HT1080 cells	1 μM	30 min	KW-2449 inhibited Erastin-induced ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
Adult/T315I	0.4 µM	48 h	KW2449 synergistically increased apoptosis with HDACIs	Clin Cancer Res. 2011 May 15;17(10):3219-32.
liver cancer HepG2 cells	1 μM	30 min	KW-2449 inhibited Erastin-induced ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
LAMA84	0.4 µM	48 h	KW2449 synergistically increased apoptosis with HDACIs	Clin Cancer Res. 2011 May 15;17(10):3219-32.
human lung cancer H1299 cells	1 μM	30 min	KW-2449 inhibited RSL3-induced ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
human colon cancer HT29 cells	1 μM	30 min	KW-2449 inhibited RSL3-induced ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
K562	0.4 µM	72 h	KW2449 synergistically increased apoptosis with HDACIs	Clin Cancer Res. 2011 May 15;17(10):3219-32.
neurons	1 µM	20 days	to treat morphological deficits in MECP2-KO neurons, significantly enhancing dendritic length, branch number, and morphological complexity	Stem Cell Res Ther. 2022 Dec 27;13(1):534.
cerebral organoids	1 µM	49 days	to treat developmental defects in MECP2-KO cerebral organoids, restoring the proportion of cycling hNPs and the number of TBR1+ and CTIP2+ post-mitotic neurons	Stem Cell Res Ther. 2022 Dec 27;13(1):534.
RAW 264.7 cells	1 µM	24 h	KW2449 reduced LZ-induced necroptosis and decreased the expression of inflammatory cytokines.	Front Immunol. 2023 Mar 13;14:1135014.
mouse embryonic fibroblast cells (MEFs)	1 μM	30 min	KW-2449 inhibited cisplatin-induced lipid peroxidation and ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
human renal proximal tubule HK2 cells	1 μM	30 min	KW-2449 inhibited RSL3-induced ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
K562	0.4 µM	72 h	To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.	Clin Cancer Res. 2011 May 15;17(10):3219-32.
LAMA84	0.4 µM	48 h	To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.	Clin Cancer Res. 2011 May 15;17(10):3219-32.
BV173/E255K	0.4 µM	48 h	To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.	Clin Cancer Res. 2011 May 15;17(10):3219-32.
Adult/T315I	0.4 µM	48 h	To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.	Clin Cancer Res. 2011 May 15;17(10):3219-32.

Cell Line

Concentration

Treated Time

Description

References

BV173/E255K

0.4 µM

48 h

KW2449 synergistically increased apoptosis with HDACIs

Clin Cancer Res. 2011 May 15;17(10):3219-32.

human fibrosarcoma HT1080 cells

1 μM

30 min

KW-2449 inhibited Erastin-induced ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

Adult/T315I

0.4 µM

48 h

KW2449 synergistically increased apoptosis with HDACIs

Clin Cancer Res. 2011 May 15;17(10):3219-32.

liver cancer HepG2 cells

1 μM

30 min

KW-2449 inhibited Erastin-induced ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

LAMA84

0.4 µM

48 h

KW2449 synergistically increased apoptosis with HDACIs

Clin Cancer Res. 2011 May 15;17(10):3219-32.

human lung cancer H1299 cells

1 μM

30 min

KW-2449 inhibited RSL3-induced ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

human colon cancer HT29 cells

1 μM

30 min

KW-2449 inhibited RSL3-induced ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

K562

0.4 µM

72 h

KW2449 synergistically increased apoptosis with HDACIs

Clin Cancer Res. 2011 May 15;17(10):3219-32.

neurons

1 µM

20 days

to treat morphological deficits in MECP2-KO neurons, significantly enhancing dendritic length, branch number, and morphological complexity

Stem Cell Res Ther. 2022 Dec 27;13(1):534.

cerebral organoids

1 µM

49 days

to treat developmental defects in MECP2-KO cerebral organoids, restoring the proportion of cycling hNPs and the number of TBR1+ and CTIP2+ post-mitotic neurons

Stem Cell Res Ther. 2022 Dec 27;13(1):534.

RAW 264.7 cells

1 µM

24 h

KW2449 reduced LZ-induced necroptosis and decreased the expression of inflammatory cytokines.

Front Immunol. 2023 Mar 13;14:1135014.

mouse embryonic fibroblast cells (MEFs)

1 μM

30 min

KW-2449 inhibited cisplatin-induced lipid peroxidation and ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

human renal proximal tubule HK2 cells

1 μM

30 min

KW-2449 inhibited RSL3-induced ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

K562

0.4 µM

72 h

To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.

Clin Cancer Res. 2011 May 15;17(10):3219-32.

LAMA84

0.4 µM

48 h

To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.

Clin Cancer Res. 2011 May 15;17(10):3219-32.

BV173/E255K

0.4 µM

48 h

To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.

Clin Cancer Res. 2011 May 15;17(10):3219-32.

Adult/T315I

0.4 µM

48 h

To evaluate the effect of KW2449 combined with HDAC inhibitors on apoptosis, results showed that combined treatment significantly increased apoptosis.

Clin Cancer Res. 2011 May 15;17(10):3219-32.

KW-2449 动物实验

Species Rats C57BL/6 mice BALB/C mice BALB/C mice	Animal Model Collagen-induced arthritis (CIA) model Cisplatin-induced acute kidney injury (AKI) model IM-resistant ALL xenograft model IM-resistant ALL xenograft model	Administration	Dosage	Frequency	Description	References
Rats	Collagen-induced arthritis (CIA) model	Oral gavage	7 mg/kg	Once daily for 28 days	KW2449 reduced joint swelling, joint bone destruction, tissue damage, and plasma inflammatory cytokine levels in CIA rats.	Front Immunol. 2023 Mar 13;14:1135014.
C57BL/6 mice	Cisplatin-induced acute kidney injury (AKI) model	Oral gavage	10 mg/kg	Once daily for 72 hours	KW-2449 alleviated cisplatin-induced renal damage by inhibiting lipid peroxidation and ferroptosis.	Cell Death Dis. 2024 Oct 21;15(10):764.
BALB/C mice	IM-resistant ALL xenograft model	Oral or intraperitoneal injection	32 mg/kg	5 days/week for 4 weeks	To evaluate the therapeutic effect of KW2449 combined with HDAC inhibitors on IM-resistant ALL, results showed that combined treatment significantly prolonged survival and reduced tumor signal.	Clin Cancer Res. 2011 May 15;17(10):3219-32.
BALB/C mice	IM-resistant ALL xenograft model	Oral and intraperitoneal injection	32 mg/kg	5 days/week, continuous treatment	Combination of KW2449 with HDACIs significantly prolonged the survival of mice bearing IM-resistant ALL cells	Clin Cancer Res. 2011 May 15;17(10):3219-32.

Species

Rats C57BL/6 mice BALB/C mice BALB/C mice

Animal Model

Collagen-induced arthritis (CIA) model Cisplatin-induced acute kidney injury (AKI) model IM-resistant ALL xenograft model IM-resistant ALL xenograft model

Administration

Dosage

Frequency

Description

References

Rats

Collagen-induced arthritis (CIA) model

Oral gavage

7 mg/kg

Once daily for 28 days

KW2449 reduced joint swelling, joint bone destruction, tissue damage, and plasma inflammatory cytokine levels in CIA rats.

Front Immunol. 2023 Mar 13;14:1135014.

C57BL/6 mice

Cisplatin-induced acute kidney injury (AKI) model

Oral gavage

10 mg/kg

Once daily for 72 hours

KW-2449 alleviated cisplatin-induced renal damage by inhibiting lipid peroxidation and ferroptosis.

Cell Death Dis. 2024 Oct 21;15(10):764.

BALB/C mice

IM-resistant ALL xenograft model

Oral or intraperitoneal injection

32 mg/kg

5 days/week for 4 weeks

To evaluate the therapeutic effect of KW2449 combined with HDAC inhibitors on IM-resistant ALL, results showed that combined treatment significantly prolonged survival and reduced tumor signal.

Clin Cancer Res. 2011 May 15;17(10):3219-32.

BALB/C mice

IM-resistant ALL xenograft model

Oral and intraperitoneal injection

32 mg/kg

5 days/week, continuous treatment

Combination of KW2449 with HDACIs significantly prolonged the survival of mice bearing IM-resistant ALL cells

Clin Cancer Res. 2011 May 15;17(10):3219-32.

KW-2449 参考文献

KW-2449 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.01mL

0.60mL

0.30mL

15.04mL

3.01mL

1.50mL

30.08mL

6.02mL

3.01mL

KW-2449 技术信息

CAS号	1000669-72-6
分子式	C₂₀H₂₀N₄O
分子量	332.4
SMILES Code	O=C(C1=CC=C(C=CC2=NNC3=C2C=CC=C3)C=C1)N4CCNCC4
MDL No.	MFCD18385006

别名
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(150.42 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

KW-2449 {[allProObj[0].p_purity_real_show]}

KW-2449 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

KW-2449 质控信息

KW-2449 生物活性

KW-2449 细胞实验

KW-2449 动物实验

KW-2449 参考文献

KW-2449 实验方案

KW-2449 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

靶点	Aurora A Aurora A, IC50:48 nM Abl Abl, IC50:14 nM Abl (T315I), IC50:4 nM
描述	KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A, and showing little effect on PDGFRβ, IGF-1R, EGFR.

Aurora A	Aurora A, IC50:48 nM
Abl	Abl, IC50:14 nM Abl (T315I), IC50:4 nM

KW-2449 {[allProObj[0].p_purity_real_show]}

KW-2449 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

KW-2449 质控信息

KW-2449 生物活性

KW-2449 细胞实验

KW-2449 动物实验

KW-2449 参考文献

KW-2449 实验方案

KW-2449 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

KW-2449 纯度/质量文件产品仅供科研